| 摘 要： | Systemic juvenile idiopathic arthritis (sJIA) is a sub - type of juvenile idiopathic arthritis. It is an inflammatory disease characterized by high fever, rash and/or systemic multiple organ dysfunction. Macrophage activation syndrome(MAS) is a complication of rheumatic diseases. It is almost secondary to sJIA in children. At present, the etiology of sJIA and MAS is not clear, the early clinical features are lack of specificity. So it's easily to miss diagnosis, misdiagnosis, delay the opportunity of treatment, even lead to death. Although the understanding of sJIA and MAS has been gradually deepened in recent years, how to timely and reasonably diagnose and treat it is still a common problem encountered by the children's rheumatology doctors. In order to further standardize the diagnosis, treatment, drug reduction and withdrawal strategies of sJIA and sJIA combined with MAS, and improve the overall prognosis of the disease, four professional academic organizations of children's rheumatology, including the Subspecialty Group of Rheumatology, the Society of Pediatrics, Chinese Medical Association, jointly formulated the Exerts consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis combined with macrophage activation syndrome (2022 version) , to better guide clinical diagnosis and treatment. © 2022 ＣｈｉｎＪＡｐｐｌＣｌｉｎＰｅｄｉａｔ. All rights reserved.
|
